Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Disc Medicine, Inc. (IRON)

Core Viewpoint - Disc Medicine, Inc. is under investigation for potential violations of federal securities laws following the FDA's issuance of a Complete Response Letter (CRL) for its lead therapeutic candidate, bitopertin, which delays approval and impacts the company's valuation significantly [1][2][5]. Group 1: FDA Response and Impact - On February 13, 2026, the FDA issued a CRL for bitopertin, indicating that the application cannot be approved in its current form and requires additional data submissions [2]. - Bitopertin was positioned as a transformative therapy for approximately 4,000 Erythropoietic protoporphyria (EPP) patients in the U.S., and the CRL delays potential approval until at least 2027, eliminating near-term commercial revenue [3]. - Following the CRL announcement, Disc shares declined by 21.9%, reflecting the market's prior expectations of a favorable FDA outcome based on the company's communications [4]. Group 2: Investigation Focus - The investigation by Levi & Korsinsky is centered on whether Disc and its senior executives made statements regarding the regulatory prospects of bitopertin that did not fully disclose the risks and challenges faced in interactions with the FDA prior to the CRL [5].